HLN PDMR notification: 37 shares disclosed at £3.4352
Rhea-AI Filing Summary
Haleon plc filed a Form 6-K reporting notifications of transactions by persons discharging managerial responsibilities on 10 October 2025. The disclosure shows an allotment of £3.4352 per share for 37 matching shares as the reported trade. The notice is a regulatory disclosure under the UK Market Abuse Regulation and provides routine transparency about insider dealings. The report lists the company's well-known consumer health brands and is signed by the Company Secretary on 10 October 2025.
Positive
- Regulatory compliance — the company disclosed PDMR transactions under the UK Market Abuse Regulation
- Specific trade detail provided: £3.4352 price and 37 matching shares, enabling transparent record-keeping
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Haleon (HLN) disclose in the Form 6-K dated October 10, 2025?
The company disclosed notifications of transactions by PDMRs showing a trade of 37 matching shares at £3.4352 per share on 10 October 2025.
Does the Form 6-K indicate material corporate transactions or earnings information for HLN?
No. The filing contains a PDMR shareholding notification and a list of brands; it does not include earnings, major transactions, or financial tables.
Which brands does Haleon list in the filing?
The filing lists brands including Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.
Who signed the Form 6-K for Haleon and when was it signed?
The report was signed by the Company Secretary and dated October 10, 2025.
Is the disclosed PDMR trade likely to be investor‑material?
The filing provides a small reported volume (37 shares) without additional context; this routine disclosure alone does not indicate a material corporate event.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2025
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
10
October 2025 - “Director/PDMR
Shareholding”
|
99.1
Haleon plc: Director/PDMR
Shareholding
10 October 2025: Haleon
plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces
notification and public disclosure in accordance with the
requirements of The UK Market Abuse Regulation of Transactions by
Persons Discharging Managerial Responsibilities
("PDMRs").
On 10 October 2025, the Company received notification of the
following transactions as detailed below.
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
||||
|
a)
|
Name
|
Adrian Morris
|
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
General Counsel - PDMR
|
|||
|
b)
|
Initial notification /Amendment
|
Initial Notification
|
|||
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction
monitor
|
||||
|
a)
|
Name
|
Haleon plc
|
|||
|
b)
|
LEI
|
549300PSB3WWEODCUP19
|
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
||||
|
a)
|
Description of the financial instrument, type of
instrument
|
Ordinary Shares of £0.01 each
|
|||
|
Identification code
|
GB00BMX86B70
|
||||
|
b)
|
Nature of the transaction
|
Acquisition of Partnership Shares and award of Matching Shares
under the Company's Share Reward Plan
|
|||
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
|
£3.4352
|
37
|
|
|
|
|
|
£Nil
|
37 (Matching Shares)
|
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|||
|
- Aggregated volume
|
74
|
||||
|
- Price
|
|
||||
|
e)
|
Date of the transaction
|
9 October 2025
|
|||
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|||
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
||||
|
a)
|
Name
|
Tamara Rogers
|
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Chief Marketing Officer - PDMR
|
|||
|
b)
|
Initial notification /Amendment
|
Initial Notification
|
|||
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction
monitor
|
||||
|
a)
|
Name
|
Haleon plc
|
|||
|
b)
|
LEI
|
549300PSB3WWEODCUP19
|
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
||||
|
a)
|
Description of the financial instrument, type of
instrument
|
Ordinary Shares of £0.01 each
|
|||
|
Identification code
|
GB00BMX86B70
|
||||
|
b)
|
Nature of the transaction
|
Acquisition of Partnership Shares and award of Matching Shares
under the Company's Share Reward Plan
|
|||
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
|
£3.4352
|
37
|
|
|
|
|
|
£Nil
|
37 (Matching Shares)
|
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|||
|
- Aggregated volume
|
74
|
||||
|
- Price
|
|
||||
|
e)
|
Date of the transaction
|
9 October 2025
|
|||
|
f)
|
Place of the transaction
|
London Stock Exchange (XLON)
|
|||
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans six major categories - Oral Health,
Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory
Health, Digestive Health and Therapeutic Skin Health and Other. Its
long-standing brands - such as Advil, Centrum, Otrivin,
Panadol, parodontax, Polident, Sensodyne,
Theraflu and Voltaren - are built on trusted science, innovation
and deep human understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON
PLC
(Registrant)
|
|
|
Date:
October 10, 2025
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|